Treatment of acute mania - From clinical trials to recommendations for clinical practice

Human Psychopharmacology

Volumn 20, Issue 1, 2005, Pages 15-26

  Bourin, Michel ^a   Lambert, Olivier ^a   Guitton, Bernard ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Acute mania; Antipsychotics; Normothymic agents; Treatment of mania

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; CYTOCHROME P450 3A4; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM SALT; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PLACEBO; PROLACTIN; RISPERIDONE; TOPIRAMATE; TRANQUILIZER; VALPROATE SEMISODIUM; VALPROIC ACID; VALPROMIDE; ZUCLOPENTHIXOL;

ACUTE DISEASE; ADD ON THERAPY; AGRANULOCYTOSIS; AKATHISIA; ASTHENIA; ATAXIA; BIPOLAR DISORDER; BODY WEIGHT DISORDER; BRAIN DISEASE; CEREBELLUM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; CONSENSUS; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TOLERABILITY; DYSTONIA; EUROPE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCREASED APPETITE; LEUKOPENIA; MANIA; METHODOLOGY; MONOTHERAPY; MOOD DISORDER; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; NEUTROPENIA; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RAPID CYCLING BIPOLAR DISORDER; REVIEW; SEDATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; UNITED STATES; WEIGHT GAIN; XEROSTOMIA;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; HUMANS; PRIMARY HEALTH CARE;

EID: 13644262989     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.657     Document Type: Review

References (84)

1. Abou-Saleh MT. 1993. Who responds to prophylactic lithium therapy? Br J Psychiatry 163: 20-26.
2. American Psychiatric Association. 2002. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159(Suppl. 4): 1-50.
3. Baldessarini R, Tondo L. 2000. Does lithium still work? Evidence of stable response over three decades. Arch Gen Psychiatry 57: 187-190.
4. Ballenger JC, Post RM. 1980. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137 782-790.
5. Barnabi B, Scherillo P, Benedetti F, et al. 1997. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 12: 109-112.
6. Bourin M, Auby P, Marcus RN, et al. Aripiprazole vs. haloperidol for maintained treatment effect in acute mania. Presented at the American Psychiatric Association, 156th Annual Meeting, San Francisco, CA, 17-22 May 2003.
7. Bourin M, Lambert O, Guitton B. 2002. Evaluation des médicaments dans le traitement de la manie aiguë. Lettre Pharmacol 16: 149-153.
8. Bowden CL, Brugger AM, Swann AC, et al. 1994. Efficacy of divalproex vs. lithium and placebo in the treatment of mania: the Depakote Study Group. JAMA 271: 918-924.
9. Bowden C, Calabrese JR, Ascher J, et al. Spectrum of efficacy of lamotrigine in bipolar disorder: overview of double-blind placebo-controlled studies. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, 10-14 December 2000, San Juan, Puerto Rico. (Abstracts of the meeting.)
10. Bowden CL, Calabrese JR, McElroy SL, et al. 1999. The efficacy of lamotrigine in rapid cycling and non-rapid cycling bipolar disorders. Biol Psychiatry 45: 953-958.
11. Brady KT, Sonne SC, Anton R, et al. 1995. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 56: 118-121.
12. Brown R. 1989. U.S. experience with valproate in manic depressive illness: a multicentre trial. J Clin Psychiatry 50 Suppl. 1): 13-16.
13. Brown D, Silverstone T, Cookson J. 1989. Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol 4: 229-238.
14. Calabrese JR. Topiramate versus placebo in mania. Presented at the 153rd Annual Meeting of the American Psychiatric Association, 13-18 May 2000, Chicago, USA. Abstracts of the Congress.
15. Calabrese JR, Bowden CL, McElroy SL, et al. 1999. Spectrum of activity of lamotrigine in treatment of refractory bipolar disorder. Am J Psychiatry 156: 1019-1023.
16. Calabrese JR, Fatemi SH, Kujawa M. 1996. Predictors of response to mood stabilizers. J Clin Psychiatry 16(Suppl. 1): 24-31.
17. Calabrese JR, Kimmel SE, Woyshville MJ, et al. 1996. Clozapine for treatment of acute mania. Am J Psychiatry 153: 759-764.
18. Calabrese JR, Shelton MD, Bowden CL, et al. 2001. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 62(Suppl. 14): 34-41.
19. Calabrese JR, Shelton MD, Rapport DJ, et al. 2002. Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry 63(Suppl. 3): 5-9.
20. Calabrese JR, Woyshville MJ, Kimmel SE, et al. 1993. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 13: 280-283.
21. Carta MG, Hardoy MC, Hardoy MJ, et al. 2003. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord 75: 83-91.
22. Chouinard G, Young SN, Annable L. 1983. Antimanic effect of clonazepam. Biol Psychiatry 18: 451-466.
23. de Camargo OA, Bode H. 1999. Agranulocytosis associated with lamotrigine. Br Med J 318: 1179.
24. Edwards R, Stephenson U, Flewet T. 1991. Clonazepam in acute mania: a double-blind study. Aust NZ J Psy 25: 238-242.
25. Frye MA, Ketter TA, Kimbrell TA, et al. 2000. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorder. J Clin Psychopharmacol 20: 607-614.
26. Goodwin GM: Consensus Group of the British Association for Psychopharmacology. 2003. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17: 149-173.
27. Goodwin FK, Murphy DL, Bunney WE Jr. 1969. Lithium-carbonate in depression and mania: a longitudinal double blind study. Arch Gen Psychiatry 21: 486-496.
28. Greil W, Keindienst N. 1999. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 14: 277-281.
29. Jefferson JW, Greist JH, Acherman DL, et al. 1987. Lithium Encyclopaedia for Clinical Practice, 2nd edn. American Psychiatric Press: Washington DC, 744.
30. Kahn D, Stevenson E, Douglas CJ. 1988. Effect of sodium valproate in three patients with organic brain syndromes. Am J Psychiatry 145: 1010-1011.
31. Kane JM. 1999. Tardive dyskinesia in affective disorders. J Clin Psychiatry 60(Suppl. 5): 43-47.
32. Keck PE, Mendlewicz J, Calabrese JR, et al. 2000. A review of randomised, controlled clinical trials in acute mania. J Affect Disord 59(Suppl. 1): S31-S37.
33. Keller MB, Lavori PW, Coryell W, et al. 1986. Differential outcome of pure manic, mixed cycling, and pure depressive episodes in patients with bipolar illness. JAMA 255: 918-924.
34. Ketter TA, Wang PW. 2002. Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. J Clin Psychiatry 63(Suppl. 3): 21-25.
35. Kukopulos A, Reginaldi D, Laddomada P, et al. 1980a. Course of the manic-depressive cycle and change cause by treatments. Pharmacopsy 13: 156-167.
36. Kukopulos A, Reginaldi D, Laddomada P, et al. 1980b. Course of the manic-depressive cycle and changes cause by treatment. Pharmacopsy Neuropsychopharmacol 13: 156-167.
37. Lambert O, Veyrac G, Armand C, et al. 2002. Lamotrigine-induced neutropenia following two attempts to increase dosage above 50 mg/d with recovery between episodes. Adv Drug React Toxicol Rev 21: 157-159.
38. Maj M. 1992. Clinical prediction of response to lithium prophylaxis in bipolar patients: a clinical update. Lithium 3 15-21.
39. McElroy SL, Keck PE, Pope HP, et al. 1992. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 12(Suppl. 1): 42-52.
40. McElroy SL, Keck PE, Stanton SP, et al. 1996. A randomised comparison of divalproex oral loading initial versus haloperidol in the treatment of acute psychotic mania. J Clin Psychiatry 57: 142-146.
41. McElroy SL, Pope HG, Keck PE, et al. 1989. Valproate in psychiatric disorders: literature review and clinical guidelines. J. Clin. Psychiatry 50(Suppl): 23-29.
42. Meehan K, Zhang F, David S, et al. 2001. A double-blind, randomised comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 21: 389-397.
43. Muller-Oerlinghausen B, Retzow A, Henn FA, et al. 2002. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomised, double-blind, placebo-controlled, multicentre study, European Valproate Mania Study Group. J Clin Psychopharmacol 20: 195-203.
44. Nasrallah HA, Churchill CM, Hamdan-Allan GA. 1993. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 145: 1455-1456.
45. Okuma T. 1993. Effect of carbamazepine and lithium on affective disorders. Neuropsychobiology 27: 138-145.
46. Okuma T, Inanaga K, Otsuki S, et al. 1976. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology 66: 211-217.
47. Okuma T, Yamashita I, Takahaschi R, et al. 1990. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsy 23: 143-150.
48. Page RL, O'Neil MG, Yarbrough DR, et al. 1998. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 18: 392-398.
49. Pande A, Crockatt J, Janney C, et al. 2000. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipol Disord 2: 249-255.
50. Peselow ED, Fieve RR, Difigli C, et al. 1994. Lithium prophylaxis of bipolar illness: the value of combination treatment. Br J Psychiatry 164: 208-218.
51. Pisani F, Fazio A, Oteri G, et al. 1986. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia 27: 548-552.
52. Platman SR. 1970. A comparison of lithium carbonate and chlorpromazine in mania. Am J Psychiatry 127: 351-353.
53. Poolsup N, Li Wan Po A, de Oliveira IR. 2000. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 25: 139-156.
54. Pope GH, McElroy SL, Keck PE, et al. 1991. Valproate in the treatment of acute mania. Arch Gen Psychiatry 48: 62-68.
55. Post RM. 1990. Non-lithium treatment for bipolar disorder. J Clin Psychiatry 51(Suppl. 8): 9-16.
56. Sachs GS. 2000. Safety and efficacy of risperidone versus placebo in combination with lithium or valproate in the treatment of manic phase of the bipolar disorder (abstract). Int J Neuropsychopharmacol 3(Suppl. 1): S143.
57. Sachs GS, Grossman F, Ghaemi SN, et al. 2002. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo controlled comparison of efficacy and safety. Am J Psychiatry 159: 1146-1154.
58. Sachs B, Ronnau AC, von Schmiedeberg S. 1997. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 195: 60-64.
59. Schaff MR, Fawcett F, Zajecka JM. 1993. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 54: 380-384.
60. Schlienger RG, Shapiro LE, Shear NH. 1998. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 39(Suppl. 7): S22-S26.
61. Segal J, Berk M, Brook S. 1998. Risperidone compared with both lithium and haloperidol in mania: a double blind randomised controlled trial. Clin Neuropharmacol 21: 176-180.
62. Sernyak MJ, Godleski LS, Griffin RA, et al. 1997. Chronic neuroleptic exposure in bipolar outpatients. J Clin Psychiatry 58: 193-195.
63. Shi L, Namjoshi MA, Zhang F, et al. 2002. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol 17: 227-237.
64. Shull WK, Sapira JD. 1970. Critique of studies of lithium salts in the treatment of mania. Am J Psychiatry 127: 218-222.
65. Solvason HB. 2000. Agranulocytosis associated with lamotrigine. Am J Psychiatry 157: 1704.
66. Spina E, Pisani F, Peruca E. 1996. Clinically significant pharmacokinetic drug interactions with carbamazepine. Clin Pharmacokinet 31: 198-214.
67. Spring G, Frankel M. 1981. New data on lithium and haloperidol incompatibility. Am J Psychiatry 138: 818-821.
68. Stromgren LS, Boller S. 1985. Carbamazepine in treatment and prophylaxis of manic-depressive disorder. Psychiatr Dev 4: 349-367.
69. Suppes T, Dennehy E, Swann AC, et al. 2002. Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder 2000. J Clin Psychiatry 63: 288-299.
70. Suppes T, Webb A, Paul B, et al. 1999. Clinical outcome in a randomised 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and an history of mania. Am J Psychiatry 156: 1164-1169.
71. Swann AC, Bowden CL, Calabrese JR, et al. 2002. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacol 26: 530-536.
72. Swann AC, Bowden CL, Morris D, et al. 1997. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 54: 37-42.
73. Tohen M, Baker RW, Altshuler LL, et al. 2002a. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 159: 1011-1017.
74. Tohen M, Chengappa KN, Suppes T, et al. 2002b. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially non-responsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59: 62-69.
75. Tohen M, Jacobs TG, Grundy SL, et al. 2000. Efficacy of olanzapine in acute bipolar mania: a double blind, placebo-controlled study. Arch Gen Psychiatry 57: 841-849.
76. Tohen M, Sanger TM, McElroy SL, et al. 1999. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 156: 702-709.
77. Totten M, Zarate CA. 1998. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 59(Suppl. 1): 38-48.
78. Tohen M, Zarate CA, Centorrino F, et al. 1996. Risperidone in the treatment of mania. J Clin Psychiatry 57: 249-253.
79. Tohen M, Zang F, Taylor CC, et al. 2001. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 65: 85-93.
80. Vieta E, Goikolea JM, Corbella B, et al. 2001. Group for the Study of Risperidone in Affective Disorders (GSRAD). Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorder: results from a 6-month, multicentre, open study. J Clin Psychiatry 62: 818-825.
81. Yatham LN. 2002a. Innovations in the management of bipolar disorders. J Clin Psychiatry 63(Suppl. 3): 3-4.
82. Yatham LN. 2002b. The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry 63(Suppl. 3): 10-14.
83. Zarate CA, Quiroz JA. 2003. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord 5: 217-225.
84. Zarate CA, Tohen M, Banov MD, et al. 1995. Is clozapine a mood stabilizer? J Clin Psychiatry 56: 108-112.